Category: 8. Health

  • Single-cell sequencing maps immune changes in chronic myeloid leukemia

    Single-cell sequencing maps immune changes in chronic myeloid leukemia

    Chronic myeloid leukemia (CML) is a hematopoietic malignancy characterized by BCR-ABL1 gene fusion. The immune microenvironment, implicated in relapse and drug resistance, poses significant challenges towards CML treatment. Identifying immune microenvironment changes at the single-cell level may therefore aid in the development of personalized targeted therapies for CML.

    In a new study published in the Genes & Diseases journal, researchers from Huazhong Agricultural University, Wuhan University, Chongqing Medical University, Third Military Medical University (Army Medical University), and Huazhong University of Science and Technology conducted multi-level single-cell sequencing to systematically map the bone marrow T cell atlas and the interaction between bone marrow cells and T cells in CML patients.

    A comparison of the bone marrow cells from healthy and CML donors showed an increase in the CD8 T cell population along with a decrease in the CD4 T cell population in CML patients, indicating that CML induces enhanced T cell toxicity and an immunosuppressive state. Further analysis of gene expression revealed distinct alterations in both cell populations between the CML and healthy groups.

    The authors identified 13 distinct T-cell populations in the bone marrow of healthy and CML patients. Of these, the proportional distribution of CD4 naive, CD8 terminal effector (TE), and CD4 TE cells varied between the CML and healthy bone marrow samples. While the proportion of CD4 naïve T cells in CML patients was significantly lower than in the healthy samples, the CD8 TE cells were significantly increased, indicating that CD8 TE and CD4 naive cells regulate the CML immune microenvironment.

    Single-cell T cell sequencing and T cell receptor (TCR) sequencing showed i) a decrease in TCR diversity in CML; ii) an expansion of CD8 TE cells in CML; iii) enrichment of a large number of CD8 TE differential genes in key signaling pathways; and iv) significant changes in CML CD8TE cells, suggesting that a large part of the gene expression changes in CD8 T cells in CML originate from CD8 TE cells.

    Further analysis unraveled a complex communication network between T cell subsets and bone marrow microenvironment cells. The proportion of CD8 TE cells was found to significantly correlate with neutrophils, with a significant enrichment of neutrophil-7 subtype, suggesting that this subtype is most associated with CD8 TE cells.

    Analysis of the ligand-receptor interaction between neutrophil-7 and CD8 TE cells revealed significant differences in ligand-receptor pairs between CML and healthy patients. The NR3C1_FASLG pair stimulates the expansion of effector T cells, while TNFSF14_TNFRSF14 promotes cytotoxicity. These results suggest a significant interaction between neutrophil-7 and CD8 TE cells and may jointly promote the occurrence and development of CML.

    In conclusion, this study utilized multi-level single-cell sequencing to comprehensively characterize the T cell subsets in CML patients, revealing “significant changes in the number and gene expression of T cells, diversity of TCR repertoire, cell-cell communication network, and the potential inter-relationship between bone marrow microenvironment and T cell subsets”, thus providing a valuable resource to understand immune changes in CML.

    Source:

    Journal reference:

    Zhuo, C., et al. (2025). Single-cell sequencing reveals the expansion and diversity of T cell subsets in the bone marrow microenvironment of chronic myeloid leukemia. Genes & Diseases. doi.org/10.1016/j.gendis.2025.101626.

    Continue Reading

  • Pro-inflammatory diet in pregnancy tied to diabetes in offspring

    Pro-inflammatory diet in pregnancy tied to diabetes in offspring

    Pro-inflammatory diet in pregnancy tied to diabetes in offspring | Image Credit: © vaaseenaa – stock.adobe.com.Pro-inflammatory diet in pregnancy tied to diabetes in offspring | Image Credit: © vaaseenaa – stock.adobe.com.

    A maternal diet characterized by high intake of pro-inflammatory foods during pregnancy may increase the risk of type 1 diabetes in offspring, according to findings from a large prospective cohort study in Denmark published in the Journal of Epidemiology & Community Health.1,2

    Researchers evaluated data from 67,701 mother-child pairs enrolled in the Danish National Birth Cohort (DNBC) between 1996 and 2002. The study excluded mothers with pre-existing diabetes or implausible dietary reports. Maternal diet was assessed at approximately 25 weeks of gestation using a comprehensive 360-item food frequency questionnaire. An empirical dietary inflammatory index (EDII) score was calculated to quantify the inflammatory potential of each participant’s diet, with higher scores indicating a more pro-inflammatory dietary pattern.

    Over an average follow-up period of 17.6 years, 281 children (0.42%) were diagnosed with type 1 diabetes. The investigators observed a statistically significant association between maternal EDII score and the risk of type 1 diabetes in offspring. Each 1 standard deviation increase in the EDII score was associated with a 16% increased hazard (adjusted HR, 1.16; 95% CI, 1.02–1.32) of type 1 diabetes diagnosis during childhood or adolescence.

    “A low-grade inflammatory state secondary to an altered immune cell profile, which triggers pro-inflammatory pathways, is increasingly acknowledged as a critical early-life factor influencing offspring health,” the authors wrote.

    The EDII score was derived using reduced rank regression and weighted based on associations between specific food group intake and circulating C-reactive protein (CRP) concentrations, using data from a similar Nordic cohort. Diets high in red or processed meats, low-fat dairy, pizza, French fries, margarine, and savory snacks were associated with higher EDII scores. Conversely, higher intake of alliums, tomatoes, whole grains, fruits, vegetables, tea, and dark meat fish contributed to lower (anti-inflammatory) EDII scores.

    Higher EDII scores were also associated with other maternal characteristics such as younger age, higher body mass index (BMI), smoking beyond 12 weeks of pregnancy, lower alcohol consumption, shorter breastfeeding duration, and lower socioeconomic status. However, total energy intake did not significantly differ across EDII quintiles.

    Importantly, the observed association between a pro-inflammatory diet and type 1 diabetes remained robust after adjusting for multiple potential confounders, including maternal age, BMI, smoking status, socioeconomic status, breastfeeding duration, and energy intake. Additional analyses indicated that gluten intake during pregnancy was also independently associated with elevated type 1 diabetes risk in offspring (HR per 10 g/day increase, 1.36; 95% CI, 1.09–1.71). In contrast, continued smoking during pregnancy was associated with a reduced risk (HR, 0.47; 95% CI, 0.31–0.72).

    “Of particular note is the fact that three factors during mid-pregnancy, a pro-inflammatory dietary pattern, gluten, and smoking, seemed to independently predict the child’s risk of type 1 diabetes,” the authors stated. “This suggests that mid-pregnancy may be a critical period during which the fetus is particularly susceptible to maternal lifestyle influences in relation to the individual’s later risk for developing type 1 diabetes during childhood or adolescence.”

    While the findings support the role of fetal programming in the development of autoimmune disease, the authors acknowledge limitations. As an observational study, causality cannot be established. Additionally, the child’s own diet postnatally was not assessed, and residual confounding from unmeasured factors remains possible.

    Nevertheless, the study adds to a growing body of evidence linking maternal dietary exposures during pregnancy to long-term metabolic and immune outcomes in children. The authors concluded that further studies are warranted to replicate these findings and elucidate underlying biological mechanisms.

    References:

    1. BMJ Group. ‘Inflammatory’ diet during pregnancy may raise child’s diabetes type 1 risk. Eurekalert. July 1, 2025. Accesed July 9, 2025. https://www.eurekalert.org/news-releases/1089224?

    2. Rohina Noorzae, Bjerregaard AA, Thorhallur Ingi Halldorsson, et al. Association between a pro-inflammatory dietary pattern during pregnancy and type 1 diabetes risk in offspring: prospective cohort study. Journal of Epidemiology & Community Health. Published online July 1, 2025:jech-223320. doi:https://doi.org/10.1136/jech-2024-223320

    Continue Reading

  • Coffee Benefits: 3 cups of coffee everyday can reduce the risk of fatty liver by 20%, and death from chronic liver disease by 49% |

    Coffee Benefits: 3 cups of coffee everyday can reduce the risk of fatty liver by 20%, and death from chronic liver disease by 49% |

    A recent study from the Universities of Southampton and Edinburgh reveals that coffee consumption, regardless of type, is linked to a lower risk of chronic liver disease. Researchers found that drinking coffee, especially ground coffee, reduces the risk of fatty liver disease and mortality associated with chronic liver conditions.

    Good news for coffee lovers. Your daily indulgence might be doing more than just waking you up. Your coffee consumption might be saving you from liver disease. Yes, that’s right. Coffee consumption is good for your liver. A new study has found that coffee not only has a protective effect on the liver but also reduces the risk of fatty liver and other chronic liver diseases.A study by the researchers at the Universities of Southampton and Edinburgh, UK, found that drinking any type of coffee is associated with a reduced risk of chronic liver disease. The findings are published in the journal BMC Public Health.

    Coffee and liver

    coffee

    The liver is the largest organ in the human body, and it acts as a filter that processes blood and breaks down nutrients, toxins, and waste products. The liver also plays a vital role in metabolism, digestion, and immune function. The researchers found that drinking coffee, be it caffeinated (ground or instant) or decaffeinated, is associated with a reduced risk of developing chronic liver disease and related liver conditions. The study also revealed that drinking any type of coffee was associated with a reduced risk of developing and dying from chronic liver disease compared to not drinking coffee. The benefits peaked when three to four cups were consumed every day.

    The study

    To understand the benefits of coffee on the liver, the researchers studied data from 495,585 participants with known coffee consumption. The data was collected from the UK Biobank. These participants were followed for over a median of 10.7 years, and the researchers looked to see if they developed chronic liver disease and related liver conditions.

    The findings

    coffee

    They observed that about 78% (384,818) of the participants consumed ground or instant caffeinated or decaffeinated coffee. 22% (109,767) did not drink any type of coffee. 3,600 cases of chronic liver disease, including 301 deaths, were reported during this period of study. 5,439 cases of chronic liver disease or steatosis (a buildup of fat in the liver, also known as fatty liver disease), and 184 cases of Hepatocellular carcinoma, a type of liver cancer, were also reported. The researchers found that people who drank coffee had a 21% reduced risk of chronic liver disease, a 20% reduced risk of chronic or fatty liver disease, and a 49% reduced risk of death from chronic liver disease, when compared to non-coffee drinkers. People who consumed ground coffee had the maximum benefit. This is because ground coffee contains high levels of the ingredients Kahweol and cafestol, which are beneficial against chronic liver disease in animals.

    ground coffee

    They also found that instant coffee, which has low levels of Kahweol and cafestol, was associated with a reduced risk of chronic liver disease. Though the risk reduction was less than ground coffee, it still offers benefits. “Coffee is widely accessible, and the benefits we see from our study may mean it could offer a potential preventative treatment for chronic liver disease. This would be especially valuable in countries with lower income and worse access to healthcare and where the burden of chronic liver disease is highest,” Dr Oliver Kennedy, the lead author, said.


    Continue Reading

  • Obesity-Linked Exosomes May Drive Tumor Aggressiveness in Triple-Negative Breast Cancer

    Obesity-Linked Exosomes May Drive Tumor Aggressiveness in Triple-Negative Breast Cancer

    Metabolic disorders, such as type 2 diabetes (T2D) and obesity, can drive tumor aggressiveness in triple-negative breast cancer (TNBC), according to study data published in BMC Cancer. The findings build on emerging research investigating the role of exosomes in cancer aggressiveness.1

    Breast cancer cell | Image Credit: © Mopic – stock.adobe.com

    “Obesity and [T2D] are very common and already known to worsen many cancers,” Pablo Llevenes, lead author and PhD candidate in biomolecular pharmacology at Boston University Chobanian & Avedisian School of Medicine, said in coverage by Medical Xpress. “Our research shows one clear biological way, via exosomes, how being obese can make a deadly breast cancer subtype even more aggressive.”2

    About 15% of all diagnoses of BC in the United States are TNBC, an aggressive subtype with few treatment choices since tumor cells lack human epidermal growth factor receptor 2, progesterone, and estrogen receptors. The absence of these common targets makes TNBC particularly difficult to treat, leaving patients with treatment options limited to cytotoxic agents like chemotherapy. The 5-year relative survival rate for TNBC is approximately 91%; however, this rate drops dramatically to about 12% for distant metastases.1-3

    There is growing interest in how TNBC is affected by metabolic disorders like T2D and obesity, which are both linked to more aggressive cancers and worse outcomes. Obesity is a chronic inflammatory condition that impairs how tissues respond to insulin. This ongoing inflammation leads to metabolic changes and the release of pro-inflammatory molecules—such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and leptin—into the bloodstream. These circulating factors can interact with tumors and their surrounding environment, helping to drive cancer growth and progression.1

    “However, the key causal elements that connect obesity-driven, systemic insulin resistance to increased metastatic burden and tumor progression remain poorly understood,” the authors wrote.1

    Researchers hypothesized that exosomes—small vesicles present in plasma or released by adipose tissue—may play a role in promoting tumor growth and aggressiveness, particularly in the context of obesity-driven metabolic dysfunction. To investigate this, they used a high-fat diet (HFD)–fed C57BL/6J mouse model to examine how obesity-related insulin resistance affects exosome production and function. Their focus was on how these exosomes influence the behavior of E0771 breast cancer cells, a commonly used model for TNBC, especially in the context of metabolic disease.1

    The study found that exosomes derived from HFD-induced obese, insulin-resistant mice had significantly different molecular content compared with those from lean, insulin-sensitive controls. When taken up by BC cells, these altered exosomes triggered notable molecular and phenotypic changes, including the promotion of a mesenchymal-like state—a hallmark of increased cancer aggressiveness.1

    The model’s validity was confirmed through standard metabolic testing, including oral glucose tolerance tests and intraperitoneal insulin tolerance tests, which demonstrated impaired glucose clearance and insulin response. Additionally, the HFD group showed significant weight gain, consistent with obesity and systemic insulin resistance.1

    “The differential effects observed between exosomes derived from visceral adipose tissue and plasma suggest that circulating exosomes may have a more pronounced impact on promoting a mesenchymal and metastatic phenotype in TNBC cells,” the authors concluded. “Future research should explore therapeutic strategies targeting specific signaling pathways, such as Rac1, to mitigate the pro-metastatic effects of obesity-driven insulin resistance.”1

    REFERENCES
    1. Llévenes P, Chen A, Lawton M, et al. Plasma exosomes in insulin resistant obesity exacerbate progression of triple negative breast cancer. BMC Cancer. July 9, 2025. Doi:10.1186/s12885-025-14447-8
    2. Aggressive breast cancer triggered by obesity-related blood signals, study shows. Medical Xpress. July 9, 2025. Accessed July 9, 2025. https://medicalxpress.com/news/2025-07-aggressive-breast-cancer-triggered-obesity.html
    3. Gerlach A. Sacituzumab govitecan-hziy plus pembrolizumab improves PFS in patients with metastatic triple-negative breast cancer. Pharmacy Times. April 24, 2025. https://www.pharmacytimes.com/view/sacituzumab-govitecan-hziy-plus-pembrolizumab-improves-pfs-in-patients-with-metastatic-triple-negative-breast-cancer

    Continue Reading

  • The Complexity of Aging: Managing Multimorbidity in Geriatrics

    The Complexity of Aging: Managing Multimorbidity in Geriatrics


    Continue Reading

  • COVID-19 vaccine technology adapted to develop first mRNA defense against antibiotic-resistant bacteria | The Transmission

    COVID-19 vaccine technology adapted to develop first mRNA defense against antibiotic-resistant bacteria | The Transmission

    MedExpress In this study, the researchers tested the vaccine’s resistance to the virulent pathogen that causes the disease and were able to demonstrate 100% protection against infection in animal models. The researchers now hope that this technology can be used to combat other lethal bacteria as well.

    The study was led by Tel Aviv University’s Vice President for Research and Development Prof. Dan Peer, a global pioneer in mRNA drug development and director of the Laboratory of Precision NanoMedicine at the Shmunis School of Biomedicine and Cancer Research. He worked alongside researchers from the Israel Institute for Biological Research—Dr. Uri Elia, Dr. Yinon Levy, Dr. Emmy Mamroud, and Dr. Ofer Cohen—as well as members of his own laboratory team: Dr. Edo Kon, Dr. Inbal Hazan-Halevy, and doctoral student Shani Benarroch.

    Continue Reading

  • Study finds cervical cancer risk high in women aged over 65 years

    Study finds cervical cancer risk high in women aged over 65 years

    Study finds cervical cancer risk high in women aged over 65 years | Image Credit: © heitipaves – © heitipaves – stock.adobe.com.

    The risk of cervical cancer because of human papillomavirus (HPV) remains increased in women aged at least 65 years, according to a recent study published in Gynecology and Obstetrics Clinical Medicine.1

    Current guidelines vs emerging data

    Currently, guidelines suggest that women aged 65 years and older no longer need to receive regular cervical cancer screening if their prior pap tests were normal. However, the data highlighted a rising incidence of cervical cancer in this age group, indicating a need for updated policies.

    “These data indicate that women [aged 65 and above] are a high-risk group for cervical cancer incidence and mortality, necessitating urgent attention from countries worldwide,” wrote investigators.

    The study was conducted to evaluate characteristics of high-risk HPV (hr-HPV) in older women, included rates of cervical intraepithelial neoplasia grade 2 or worse (CIN2+).2 Data from 2017 to 2023 was obtained from 628 health care facilities in Shenzhen.

    Screening methods

    In Shenzhen, a combination of HPV and cytology is used to screen patients for cervical cancer. A colposcopy referral is provided to patients with a positive HPV16/18 test, while cytology is performed for patients with a positive non-HPV16/18 high-risk genotype result.

    Regular follow-up was also provided to patients with negative hr-HPV results. Adjustments were made to care based on patient preference, such as providing a cytological examination to patients with hr-HPV negative results when requested. Pap smear or liquid-based methods were used to complete cytology.

    Digital colposcopic examinations were conducted to analyze colposcopy results. Colposcopy referrals were provided to patients with primary abnormal results, and all abnormal colposcopic findings underwent biopsies.

    Additional data collected included demographics such as ethnicity, age, region, and HPV vaccination status, as well as clinical histories such as cytology, HPV testing, and colposcopy and biopsy results. Women with missing HPV or lacking certain hr-HPC genotypes were excluded from the analysis.

    HPV and colposcopy results

    There were 2,152,766 records included in the analysis, with 57.47% of women receiving screening at hospitals. Approximately 91% of these patients were aged 25 to 54 years, and HPV vaccination was only reported in 2.25%. A negative test result for hr-HPV genotypes was reported in 91.88% of patients, a positive HPV16/18 result in 2.26%, and a positive non-HPV16/18 result in 5.86%.

    A colposcopy referral rate of 4.14% was reported, with 41.97% of colposcopies showing abnormal results. A benign histopathological diagnosis was reported in 67.65%, low-grade squamous intraepithelial lesion in 23.02%, high-grade squamous intraepithelial lesion in 8.44%, and cancer in 0.59%.

    Of patients, 0.81% were aged at least 65 years, while 99.19% were aged under 65 years. Health check-ups were the primary method of screening in 57.06% of the former group, making it the most common method in this population.

    Elderly women show higher risk indicators

    Women aged at least 65 years had higher rates of hr-HPV positivity, HPV infection, CIN2+, and cancer, at 13.67%, 22.8%, 3.33%, and 0.92%, respectively. In comparison, rates in patients aged under 65 years were 8.08%, 16.32%, 1.55%, and 0.1%, respectively. This indicated significantly increased prevalences in older patients.

    There were 174,819 total hr-HPV infections. Overall, the HPV infection rate was 8.12% and the CIN2+ infection rate was 1.83%. In patients aged at least 65 years, these rates were 13.67% and 2.23%, vs 8.08% and 1.82% among those aged under 65 years. Based on this data, the difference in HPV incidence was statistically significant, but not CIN2+.

    The 5 most common hr-HPV genotypes in patients aged under 65 years were HPV52, 16, 58, 51, and 18. In those aged at least 65 years, these were HPV 52, 16, 58, 56, and 86. Overall, this data highlighted increased hr-HPV and associated CIN2+ prevalence among women aged 65 years and older.

    “Therefore, continued cervical cancer screening is necessary for this age group, although national policies should be adapted to local conditions,” wrote investigators.

    References

    1. Women 65+ still at heightened risk of cervical cancer caused by HPV. BMJ Group. July 1, 2025. Accessed July 9, 2025. https://www.eurekalert.org/news-releases/1089214.
    2. Ye Z, Wang H, Zhong Y, et al. High-risk HPV distribution and importance of continuing cervical cancer screening of women aged 65 years and older: a study based on 2 152 766 women in China. Gynecology and Obstetrics Clinical Medicine. 2025;5(2).

    Continue Reading

  • US measles cases surge to highest level since 1992 – Financial Times

    US measles cases surge to highest level since 1992 – Financial Times

    1. US measles cases surge to highest level since 1992  Financial Times
    2. U.S. measles cases reach 33-year high as outbreaks spread  The Washington Post
    3. Measles cases surge to record high since disease was declared eliminated in the US  CNN
    4. U.S. Measles Cases Hit Highest Level Since Declared Eliminated in 2000  Johns Hopkins Bloomberg School of Public Health
    5. Measles cases in US hit three-decade high, with nearly 1,300 cases reported  New York Post

    Continue Reading

  • Popular Weight Loss Drugs May Help Treat Migraines Too

    Popular Weight Loss Drugs May Help Treat Migraines Too

    Popular diabetes and weight loss medications like Ozempic and Mounjaro show potential for treating a slew of other health issues, from osteoarthritis to binge eating. Now, new research suggests that these drugs—which belong to a class known as GLP-1s—might also help relieve migraines.

    Specifically, people with obesity and chronic migraine experienced significantly fewer headaches after a three-month stint taking liraglutide, a GLP-1 currently used to treat type 2 diabetes, researchers reported June 17 in the journal Headache.

    Migraine affects roughly 14% of the global population, making it a leading cause of disability worldwide. The new study was small, with just 31 people, and experts caution that more research is needed. Still, the findings hint at a promising new pathway for migraine relief.

    “Despite many advancements in migraine treatment in recent years, there are still many patients who suffer from intractable migraines who may benefit from emerging treatment,” said Samantha Flanagan, DO, an obesity medicine physician with Temple Health.

    To understand how GLP-1s impact migraine, the researchers recruited 26 women and five men with obesity (a body mass index over 30) and chronic migraine (headaches on at least 15 days per month).

    Participants took a daily shot containing 1.2 milligrams of liraglutide over 12 weeks. Each day, they filled out a diary detailing the intensity and frequency of their migraine symptoms. Roughly 38% of the participants experienced mild gastrointestinal side effects like nausea and constipation.

    At the end of the study, participants experienced an average of 11 fewer headache days a month. Most patients noticed improvements within the first two weeks. The participants also recorded substantial boosts in quality of life via a tool called the Migraine Disability Assessment Test.

    These improvements occurred despite the group’s BMI barely changing—on average, it dropped from 34.0 to 33.9. Because of this, the researchers concluded that GLP-1s may effectively reduce migraine symptoms, even in the absence of significant weight loss.

    Despite the promising results, the study had several limitations. First, it was observational and lacked a control group, making it unclear whether the migraine improvements were directly caused by liraglutide or influenced by other factors, Richard Baron, MD, a neurologist with Stanford Medicine, told Health.

    There was also no blinding—both the participants and the researchers were aware that they were taking the medication, which could introduce bias.

    That said, the study, while small, opens up the door for future research, Flanagan said. 

    Looking forward, Baron said he’d like to see randomized, double-blinded, placebo-controlled trials—considered the gold standard of scientific testing—examine the impact of GLP-1 drugs on migraine frequency and intensity.

    Though it’s still too soon to know if GLP-1s truly can alleviate migraine symptoms, researchers have some theories about how they might do so.

    One thought is that they may lower intracranial pressure, or pressure that builds up from the presence of fluids within the skull. Even slightly elevated pressure may sensitize the trigeminovascular system, a network of neurons in the brain closely involved in migraine. This can trigger the release of headache-causing compounds called calcitonin gene-related peptides, which lower a person’s threshold for pain and headaches.

    Previous research supports this theory: GLP-1s have been found to reduce cerebrospinal fluid secretion and intracranial pressure. Additionally, several small studies suggest that GLP-1s may improve migraine symptoms in people with idiopathic intracranial hypertension, a condition that causes chronically high intracranial pressure, said Deena E. Kuruvilla, MD, FAHS, a neurologist and medical director of the Brain Health Institute. (Notably, the new study excluded people suspected of having this condition.)

    Another possibility, according to Baron, is that GLP-1s may counteract the effects of obesity that are thought to contribute to migraine attacks, such as inflammation and fluctuations in hormones like leptin and orexin.

    “Given that the GLP-1 agonists seem to reduce inflammation associated with obesity, affect obesity-related hormonal signaling, and decrease intracranial pressure—even before weight loss is achieved—it is very reasonable to expect these medications to be helpful in reducing migraine attack severity and frequency in patients with migraine and obesity,” Baron said.

    While there are several migraine treatments available—including oral medications, injections, lifestyle changes, and neuromodulatory devices—the condition is notoriously difficult to treat.

    According to the American Headache Society, inadequate preventative medication and unidentified triggers are two of the most common reasons migraine treatments fail. In addition, many people continue to experience refractory, or intractable, headaches that are resistant to standard treatments.

    GLP-1 drugs are not yet approved by the Food and Drug Administration for migraine prevention, and treating migraine with them is not yet the standard of care, Kuruvilla said.

    But Kuruvilla told Health that she’s had several patients with refractory headaches “who had exhausted multiple traditional migraine preventives without success” take GLP-1 s and experience significant migraine relief. “I always stress that migraine improvement is a potential secondary benefit, not a guaranteed outcome,” she said.

    Baron, on the other hand, said it’s reasonable to consider GLP-1s for people with migraines and a BMI over 30. The medication may improve migraine symptoms—and boost their metabolic health to boot. “Having more tools to treat the condition is always welcome,” he said.

    Continue Reading

  • New study identifies four distinct autism subtypes with unique genetic signatures

    New study identifies four distinct autism subtypes with unique genetic signatures

    Autism is classified as a ‘spectrum’ for a reason: Each case is different. Scientists have struggled to parse through the many ways autism can manifest, much less to link these varying observable traits (called phenotypes) to underlying genetics.

    A new study in Nature Genetics from researchers at the Flatiron Institute’s Center for Computational Biology (CCB) and their collaborators leverages data from SPARK, the largest-ever study of autism, to analyze phenotypic and genotypic data from more than 5,000 participants with autism of ages 4–18. The study identifies four groups for which individuals with autism share similar traits and links them to biological processes associated with specific genetic variants. With these classifications and information about the mechanisms that drive them, scientists can work toward more precise and personalized support, such as counseling or physical therapy, and help individuals access appropriate interventions earlier.

    “A clinically grounded, data-driven subtyping of autism would really help kids get the support they need early on,” says study co-lead author Natalie Sauerwald, a CCB associate research scientist. “If you know that a person’s subtype often co-occurs with ADHD or anxiety, for example, then caregivers can get support resources in place and maybe gain additional understanding of their experience and needs.”

    Our study takes a ‘person-centered’ approach, in which we focus on the full spectrum of traits that an individual might exhibit rather than just one trait, like IQ. This approach was key to our discovery of these clinically relevant autism classes and to deciphering the biology that underlies them.”


    Olga Troyanskaya, senior research scientist and deputy director for genomics at CCB, senior author of the study

    “This study is a powerful demonstration of how data from SPARK can lead to new, clinically-relevant insights, and it also underscores the power of leveraging machine learning approaches to analyze the large amount of phenotypic and genotypic data available in SPARK,” says Kelsey Martin, executive vice president of autism and neuroscience at the Simons Foundation. “Participants in SPARK volunteer this data, and we are incredibly grateful for their generosity and their commitment to accelerating research.”

    The study was co-led by Aviya Litman of Princeton University, Sauerwald of the Flatiron Institute, and Troyanskaya, who holds joint appointments at Princeton and the Flatiron Institute, along with Christopher Y. Park and Yun Hao of the Flatiron Institute; LeeAnne Green Snyder and Jennifer Foss-Feig of the Simons Foundation; Chandra L. Theesfeld of Princeton; and Ilan Dinstein of Ben Gurion University in Israel.

    Navigating a treasure trove of data

    The project began after Sauerwald, one of the study’s first authors, spoke with autism researchers about leveraging CCB’s computational tools to analyze phenotypic and genotypic data from SPARK. SPARK, a landmark study supported by the Simons Foundation Autism Research Initiative (SFARI), is dedicated to improving the lives of people with autism by identifying the causes of autism and supporting research that informs more effective therapies, treatments, services and support. To date, the study has engaged over 150,000 people with autism and more than 200,000 of their family members.

    “I think [SPARK] is the only cohort that has this combination of extensive phenotypic data as well as genetic data,” says Sauerwald.

    But finding the best way to analyze the data would be a challenge: It includes lots of different measures collected in lots of different ways.

    “Some of our data is simple yes-or-no – does a participant have a particular trait or not?” says Sauerwald. “Other data is more nuanced, like questions that have categorical responses such as language levels, or still others that vary along a spectrum, such as the age at which a child reaches a developmental milestone.”

    The team tried many types of models to see which could best integrate the data and landed on a type called general finite mixture modeling. Mixture modeling is unique because it can handle these different data types individually and then integrate them into a single probability for each person, describing how likely they are to belong to a particular class.

    A mixture model also allowed the team to take what they call a ‘person-centered’ approach to the data. Most studies take a ‘trait-centered’ approach, in which scientists pick a trait and examine everyone who exhibits it. A person-centered approach starts with a person and examines all their traits together, much like a clinician would provide care by attending to the whole individual.

    “Our goal with the person-centered approach is to maintain representation of the whole individual so that we can more fully model their complex spectrum of traits together,” says Litman, the study’s other lead author. “Our model allowed us to do this, and to define groups of individuals with shared phenotypic profiles, which translated to clinically similar presentations.”

    Four distinct classes

    Based on the results of their model, the scientists were able to classify SPARK participants into four main groups.

    • Individuals in the first group, Social and Behavioral Challenges, have many co-occurring traits such as ADHD, anxiety disorders, depression and mood dysregulation. They also tend to display restricted or repetitive behaviors and challenges with communication. However, these individuals don’t show many developmental delays: They tend to hit their developmental milestones at the same pace as children without autism. One of the larger groups, it constitutes around 37% of the participants.
    • The second group, Mixed ASD with Developmental Delay, is the inverse of the Social and Behavioral Challenges group. While these individuals hit many of their milestones later in development than their peers without autism, they typically don’t have the same kinds of issues with anxiety, depression, mood dysregulation or disruptive behaviors. This group represents approximately 19% of the participants.
    • The third group, Moderate Challenges, includes individuals who show challenges in the areas laid out in the Social and Behavioral group, but typically not all of them, and to a lesser degree. This group also does not show developmental delays. Roughly 34% of participants fall into this category.
    • The fourth and final group, Broadly Affected, is characterized by widespread challenges, including restricted and repetitive behaviors, social communication, developmental delays, mood dysregulation, anxiety and depression. This is the smallest group, accounting for around 10% of the participants.

    Importantly, the researchers stress that these classes likely aren’t a definitive, comprehensive grouping, but rather a place to start. “This doesn’t mean that there’s necessarily only four classes,” says Troyanskaya. “I think what this demonstrates is that there are at least four classes. But having the four, which are clinically and biologically relevant, is significant.”

    Uncovering pathways at play

    The classes were established by phenotype; that is, looking only at traits and not at genetics. Then, when the scientists started to study the genetics within each class, they were surprised at the results. Specifically, the genetic variants found in individuals within each class affected biological processes in very distinct ways.

    In one analysis, the team traced how specific genetic changes affect certain genes-and then looked at what those genes actually do by studying which molecular circuits, or pathways, they act in.

    Researchers found that each autism subtype had its own biological signature.

    “There was little to no overlap in the impacted pathways between the classes,” says Litman. “And what was even more interesting is that while the impacted pathways – things like neuronal action potentials or chromatin organization – were all previously implicated in autism, each one was largely associated with a different class.”

    Remarkably, the team discovered that not just which genes were impacted by mutations-but when they were activated-differed by class.

    “In the Social and Behavioral Challenges class, quite surprisingly, the impacted genes were mostly active after birth, and this group also experienced very few developmental delays and the latest average age of diagnosis,” says Litman. “We found the opposite to be true for the ASD with Developmental Delays class, where impacted genes were mostly active prenatally.”

    Big data leads to big insights

    The team hopes this work underscores the importance of large datasets that contain many types of data.

    “I think this work highlights how important it is to have large cohorts with matched phenotypic and genetic data,” says Litman. “This way, we can connect across them and make discoveries that are not apparent by just looking at one modality alone.”

    In the future, the team would like to dive into even more types of data under this lens, including looking at the ‘non-coding’ portion of the genome. These genes constitute more than 98 percent of the genome but are less studied because they do not go on to create proteins. They still play very important roles in regulating gene expression and other cellular processes implicated in autism.

    “The more data, the more discovery,” says Sauerwald. “We know there’s a lot of contribution from the non-coding genome in autism, but we haven’t been able to study it yet in the context of these classes. So a big next step is going to be adding in this other 98 percent.”

    Source:

    Journal reference:

    Litman, A., et al. (2025). Decomposition of phenotypic heterogeneity in autism reveals underlying genetic programs. Nature Genetics. doi.org/10.1038/s41588-025-02224-z.

    Continue Reading